Biosimilars Expansion And Vertical Integration Will Reshape Long-Term Outlook

Catalysts

About Amneal Pharmaceuticals

Amneal Pharmaceuticals focuses on affordable medicines across generics, specialty drugs and biosimilars, with a growing presence in large molecule therapies.

What are the underlying business or industry changes driving this perspective?

• The acquisition of Kashiv BioSciences creates a fully integrated biosimilars platform, combining in-house R&D, manufacturing across the U.S. and India, and Amneal Pharmaceuticals commercial scale. Management expects this to support multiple biosimilar launches per year and influence long term revenue and earnings growth.
• Management describes the current period as a golden era for biosimilars, with a large wave of biologic loss of exclusivity and an estimated global biosimilars market expansion toward US$200b by 2035. This offers Amneal a broader pool of products that could contribute to revenue and adjusted EBITDA over time.
• Vertical integration in biosimilars, including planned manufacturing capacity growth from 26,000 liters in 2026 to 75,000 liters by 2028, is intended to support 3 to 5 biosimilar developments annually. This could help scale high value products and affect gross margin and net margin through greater control over costs and supply.
• A diversified portfolio across niche and larger biologics, with more than 20 biosimilar programs and management’s expectation of 6 commercial biosimilars by 2027 and additional approvals through 2030, is designed to create multiple revenue streams that can support adjusted EPS and cash flow.
• Management expects US$400m to US$500m in cumulative financial synergies from the Kashiv deal, including capturing full economics on partnered assets and tax and local incentive benefits. This is aimed at improving adjusted EBITDA, operating cash flow and net leverage over time.

Assumptions

How have these above catalysts been quantified?

• This narrative explores a more optimistic perspective on Amneal Pharmaceuticals compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts.
• The bullish analysts are assuming Amneal Pharmaceuticals's revenue will grow by 8.1% annually over the next 3 years.
• The bullish analysts assume that profit margins will increase from 4.0% today to 10.7% in 3 years time.
• The bullish analysts expect earnings to reach $409.4 million (and earnings per share of $1.2) by about July 2029, up from $122.1 million today. The analysts are largely in agreement about this estimate.
• In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 23.1x on those 2029 earnings, down from 47.1x today. This future PE is greater than the current PE for the US Pharmaceuticals industry at 15.1x.
• The bullish analysts expect the number of shares outstanding to grow by 1.57% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.11%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• The long term shift toward a larger number of vertically integrated biosimilar players, including established companies in the U.S., Europe, India and South Korea, could limit Amneal Pharmaceuticals ability to win and hold share across its more than 20 biosimilar programs, which may weigh on revenue and adjusted EBITDA in the 2030 time frame.
• The plan to scale biologics manufacturing capacity from 26,000 liters in 2026 to 75,000 liters by 2028 requires ongoing annual capital spending of about US$30 million to US$50 million for several years. If utilization of this added capacity is lower than intended, the business could face pressure on gross margin, operating margin and earnings.
• The Kashiv BioSciences acquisition increases balance sheet leverage, with net debt to adjusted EBITDA guided to 3.7x by the end of 2026 and a target of about 3x by 2028. If biosimilar launches, regulatory approvals or projected US$400 million to US$500 million in financial synergies are delayed or smaller than expected, deleveraging could take longer and interest and refinancing costs could constrain net income and cash flow.
• The long term plan depends heavily on a sustained biosimilars expansion described as a golden era, with an expectation of multiple launches a year and about US$1 billion to US$1.3 billion of biosimilar revenue by 2030. Any slower than anticipated adoption by physicians, payers or international partners could lead to lower revenue growth and softer EPS than implied by the current outlook.
• The move deeper into complex biologics, including high value products like KEYTRUDA, OPDIVO and DUPIXENT, requires large, multi year R&D and manufacturing commitments in an area with high scientific, regulatory and IP risks. Setbacks on even a few large biologics, whether from clinical, legal or capacity issues, could have an outsized effect on Amneal Pharmaceuticals long term revenue mix, gross margin and overall earnings profile.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bullish price target for Amneal Pharmaceuticals is $23.0, which represents up to two standard deviations above the consensus price target of $18.25. This valuation is based on what can be assumed as the expectations of Amneal Pharmaceuticals's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $23.0, and the most bearish reporting a price target of just $16.0.
• In order for you to agree with the more bullish analyst cohort, you'd need to believe that by 2029, revenues will be $3.8 billion, earnings will come to $409.4 million, and it would be trading on a PE ratio of 23.1x, assuming you use a discount rate of 7.1%.
• Given the current share price of $18.04, the analyst price target of $23.0 is 21.6% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.